New York—As of late 2019, the FDA had approved more than 200 drugs with pharmacogenomics (PGx) labeling information. Although about one-third of these agents are in oncology, there’s no lack of other therapeutic areas that potentially will be transformed by PGx approvals, including psychiatry, infectious diseases, neurology, cardiology, hematology, rheumatology, urology, OB-GYN and anesthesiology.
But the PGx explosion isn’t just a story about the drug pipeline;